{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:39:17Z","timestamp":1789609157478,"version":"build-2803163510"},"reference-count":205,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>A great proportion of neuromuscular diseases are immune-mediated, included myasthenia gravis, Lambert-Eaton myasthenic syndrome, acute- and chronic-onset autoimmune neuropathies (anti-MAG neuropathy, multifocal motor neuropathy, Guillain-Barr\u00e9 syndromes, chronic inflammatory demyelinating polyradiculoneuropathy, CANDA and autoimmune nodopathies), autoimmune neuronopathies, peripheral nerve hyperexcitability syndromes and idiopathic inflammatory myopathies. The detection of autoantibodies against neuromuscular structures has many diagnostic and therapeutic implications and, over time, allowed a better understanding of the physiopathology of those disorders. In this paper, we will review the main autoantibodies described in neuromuscular diseases and focus on their use in clinical practice.<\/jats:p>","DOI":"10.3389\/fneur.2024.1495205","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T14:11:30Z","timestamp":1730470290000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice"],"prefix":"10.3389","volume":"15","author":[{"given":"Valentin","family":"Loser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Vicino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Th\u00e9audin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e23043","DOI":"10.7554\/eLife.23043","article-title":"Structural insights into the molecular mechanisms of myasthenia gravis and their therapeutic implications","volume":"6","author":"Noridomi","year":"2017","journal-title":"eLife"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/0090-1229(77)90027-7","article-title":"An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis","volume":"7","author":"Lindstrom","year":"1977","journal-title":"Clin Immunol Immunopathol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cca.2015.07.030","article-title":"An update on laboratory diagnosis in myasthenia gravis","volume":"449","author":"Oger","year":"2015","journal-title":"Clin Chim Acta"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","article-title":"A systematic review of diagnostic studies in myasthenia gravis","volume":"16","author":"Benatar","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"100846","DOI":"10.1016\/j.lanwpc.2023.100846","article-title":"SCREAM study investigators. A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study","volume":"38","author":"Li","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1212\/WNL.33.10.1276","article-title":"Acetylcholine re-ceptor antibody and clinical response to thymectomy in myasthenia gravis","volume":"33","author":"Vincent","year":"1983","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/0022-510X(83)90096-5","article-title":"Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2.Clinical and serological follow-up of individual patients","volume":"58","author":"Oosterhuis","year":"1983","journal-title":"J Neurol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0022-510X(85)90144-3","article-title":"Anti- acetylcholine receptor antibodies in myasthenia gravis. Part 3. The effect of thymectomy","volume":"69","author":"Oosterhuis","year":"1985","journal-title":"J Neurol Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e114060","DOI":"10.1371\/journal.pone.0114060","article-title":"Repeated acetyl-choline receptor antibody- concentrations and association to clinical myasthenia gravis development","volume":"9","author":"Heldal","year":"2014","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1212\/WNL.31.2.220","article-title":"No direct correlation between serum antiacetylcholine receptor antibody levels and clinical state of individual patients with myasthenia gravis","volume":"31","author":"Roses","year":"1981","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00000658-198208000-00001","article-title":"A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis","volume":"196","author":"Olanow","year":"1982","journal-title":"Ann Surg"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/ene.15238","article-title":"The association between anti-acetylcholine receptor antibody level and clinical improvement in myasthenia gravis","volume":"29","author":"Marcuse","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2011\/474512","article-title":"Thymoma in myasthenia gravis: from diagnosis to treatment","volume":"2011","author":"Romi","year":"2011","journal-title":"Autoimmune Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5152\/eurasianjmed.2017.17009","article-title":"Thymectomy in myasthenia gravis","volume":"49","author":"Aydin","year":"2017","journal-title":"Eurasian J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of Thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for Management of Myasthenia Gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"J Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodr\u00edguez Cruz","year":"2015","journal-title":"JAMA Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/ene.12270","article-title":"Antibodies to clustered acetylcholine receptor: expanding the phenotype","volume":"21","author":"Devic","year":"2014","journal-title":"Eur J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"577850","DOI":"10.1016\/j.jneuroim.2022.577850","article-title":"The clinical need for clustered AChR cell-based assay testing of seronegative MG","volume":"367","author":"Masi","year":"2022","journal-title":"J Neuroimmunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/nyas.13592","article-title":"Serological and experimental studies in different forms of myasthenia gravis","volume":"1413","author":"Vincent","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cccn.2004.05.008","article-title":"Muscle-specific receptor tyrosine kinase autoantibodies-a new immunoprecipitation assay","volume":"348","author":"Matthews","year":"2004","journal-title":"Clin Chim Acta"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1007\/s00415-022-11458-4","article-title":"Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis","volume":"270","author":"Kwon","year":"2023","journal-title":"J Neurol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1212\/NXI.0000000000000357","article-title":"IgG-specific cell-based assay detects potentially pathogenic MuSK-abs in seronegative MG","volume":"4","author":"Huda","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1212\/01.WNL.0000129274.12702.92","article-title":"MuSK antibodies in AChR ab-seropositive MG vs AChR ab-seronegative MG","volume":"62","author":"Ohta","year":"2004","journal-title":"Neurology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1212757","DOI":"10.3389\/fimmu.2023.1212757","article-title":"Immunotherapies in MuSK-positive myasthenia gravis; an IgG4 antibody-mediated disease","volume":"14","author":"Vakrakou","year":"2023","journal-title":"Front Immunol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/acn3.314","article-title":"Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up","volume":"3","author":"Anderson","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/mus.26404","article-title":"Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis","volume":"59","author":"Clifford","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/acn3.26","article-title":"LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients","volume":"1","author":"Tzartos","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.nmd.2016.04.004","article-title":"Myasthenia gravis with muscle specific kinase antibodies mimicking amyotrophic lateral sclerosis","volume":"26","author":"Huijbers","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s004150050604","article-title":"Muscle autoantibodies in subgroups of myasthenia gravis patients","volume":"247","author":"Romi","year":"2000","journal-title":"J Neurol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/archneur.58.6.885","article-title":"Anti-titin antibodies in myasthenia gravis","volume":"58","author":"Yamamoto","year":"2001","journal-title":"Arch Neurol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1001\/archneur.57.11.1596","article-title":"The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies","volume":"57","author":"Romi","year":"2000","journal-title":"Arch Neurol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","article-title":"Italian recommendations for the diagnosis and treatment of myasthenia gravis","volume":"40","author":"Evoli","year":"2019","journal-title":"Neurol Sci"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/mus.20854","article-title":"Frequency of seronegativity in adult-acquired generalized myasthenia gravis","volume":"36","author":"Chan","year":"2007","journal-title":"Muscle Nerve"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1200\/JCO.2010.32.0440","article-title":"Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS","volume":"29","author":"Titulaer","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","article-title":"Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes","volume":"332","author":"Lennon","year":"1995","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-510X(96)05303-8","article-title":"Incidence of serum anti-P\/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome","volume":"147","author":"Motomura","year":"1997","journal-title":"J Neurol Sci"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0165-5728(00)00431-8","article-title":"Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line","volume":"113","author":"Benatar","year":"2001","journal-title":"J Neuroimmunol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1212\/WNL.59.5.764","article-title":"P\/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer","volume":"59","author":"Graus","year":"2002","journal-title":"Neurology"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/mus.25027","article-title":"P\/Q- and N-type calcium-channel antibodies: oncological, neurological, and serological accompaniments","volume":"54","author":"Zalewski","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1212\/01.wnl.0000903272.62514.70","article-title":"Testing for N-type voltage gated calcium channel antibody has limited utility in evaluating patients with suspected Lambert-Eaton Myasthenic syndrome","volume":"99","author":"Majed","year":"2022","journal-title":"Neurology"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1073\/pnas.97.8.4198","article-title":"Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer","volume":"97","author":"G\u00fcre","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1200\/JCO.2008.20.6169","article-title":"SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival","volume":"27","author":"Titulaer","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1212\/01.wnl.0000281663.81079.24","article-title":"SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome","volume":"70","author":"Sabater","year":"2008","journal-title":"Neurology"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1749-6632.2012.06772.x","article-title":"SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma","volume":"1275","author":"Lipka","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.autrev.2009.01.015","article-title":"SOX-1 autoantibodies in patients with paraneoplastic neurological syndromes","volume":"8","author":"Tschernatsch","year":"2009","journal-title":"Autoimmun Rev"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3389\/fimmu.2019.00769","article-title":"Caveats and pitfalls of SOX1 autoantibody testing with a commercial line blot assay in paraneoplastic neurological investigations","volume":"10","author":"Ruiz-Garc\u00eda","year":"2019","journal-title":"Front Immunol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5402\/2012\/506160","article-title":"Ganglioside biochemistry","volume":"2012","author":"Kolter","year":"2012","journal-title":"Int Scholarly Res Notices"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s004010050847","article-title":"Mapping immunoreactive epitopes in the human peripheral nervous system using human monoclonal anti-GM1 ganglioside antibodies","volume":"95","author":"O'Hanlon","year":"1998","journal-title":"Acta Neuropathol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/1531-8249(199902)45:2<168:AID-ANA6>3.0.CO;2-6","article-title":"Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome","volume":"45","author":"Ho","year":"1999","journal-title":"Ann Neurol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/jnnp.72.6.767","article-title":"Anti-GT1a IgG in Guillain-Barre syndrome","volume":"72","author":"Koga","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/CND.0000000000000241","article-title":"Anti-GQ1b Spectrum disorders","volume":"21","author":"Sawaya","year":"2019","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1212\/01.WNL.0000081229.88862.C6","article-title":"GalNAc-GD1a in human peripheral nerve","volume":"61","author":"Kaida","year":"2003","journal-title":"Neurology"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1186\/s12974-021-02301-0","article-title":"Autoantibody screening in Guillain-Barr\u00e9 syndrome","volume":"18","author":"Lleix\u00e0","year":"2021","journal-title":"J Neuroinflammation"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0022-510X(99)00174-4","article-title":"Serum antibody against a peripheral nerve myelin ganglioside, LM1, in Guillain-Barr\u00e9 syndrome","volume":"168","author":"Yako","year":"1999","journal-title":"J Neurol Sci"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1212\/WNL.57.4.736","article-title":"Anti-gal-C antibodies in GBS subsequent to mycoplasma infection: evidence of molecular mimicry","volume":"57","author":"Kusunoki","year":"2001","journal-title":"Neurology"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1212\/WNL.56.9.1227","article-title":"Guillain\u2013Barr\u00e9 syndrome associated with IgG monospecific to ganglioside GD1b","volume":"56","author":"Miyazaki","year":"2001","journal-title":"Neurology"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1529-8027.2012.00372.x","article-title":"Nodal proteins are target antigens in Guillain-Barr\u00e9 syndrome","volume":"17","author":"Devaux","year":"2012","journal-title":"J Peripher Nerv Syst"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1136\/jnnp-2011-300309","article-title":"Antiganglioside antibodies are associated with axonal Guillain\u2013Barr\u00e9 syndrome: A Japanese\u2013Italian collaborative study","volume":"83","author":"Sekiguchi","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ana.410400414","article-title":"Acute motor axonal neuropathy: An antibody-mediated attack on axolemma","volume":"40","author":"Hafer-Macko","year":"1996","journal-title":"Ann Neurol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s10096-013-2040-4","article-title":"Seroprevalence of campylobacteriosis and relevant post-infectious sequelae","volume":"33","author":"Zautner","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/brain\/122.3.449","article-title":"The distribution of ganglioside-like moieties in peripheral nerves","volume":"122","author":"Sheikh","year":"1999","journal-title":"Brain"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/ana.410310619","article-title":"Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller fisher syndrome","volume":"31","author":"Chiba","year":"1992","journal-title":"Ann Neurol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1136\/jnnp.70.1.50","article-title":"Anti-GQ1b IgG antibody syndrome: clinical and immunological range","volume":"70","author":"Odaka","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00415-008-0775-0","article-title":"Bickerstaff\u2019s brainstem encephalitis and fisher syndrome form a continuous spectrum: clinical analysis of 581 cases","volume":"255","author":"Ito","year":"2008","journal-title":"J Neurol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ana.410370218","article-title":"Serum anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller fisher syndrome","volume":"37","author":"Jacobs","year":"1995","journal-title":"Ann Neurol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1529-8027.2012.00407.x","article-title":"Clinical and serological features of acute sensory ataxic neuropathy with antiganglioside antibodies","volume":"17","author":"Rojas-Garc\u00eda","year":"2012","journal-title":"J Peripher Nerv Syst"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/jnnp-2013-305397","article-title":"Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome","volume":"85","author":"Wakerley","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1136\/jnnp-2021-326343","article-title":"IgG1pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality","volume":"92","author":"Fehmi","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/j.1471-4159.2006.04319.x","article-title":"Myelin-associated glycoprotein (MAG): past, present and beyond","volume":"100","author":"Quarles","year":"2007","journal-title":"J Neurochem"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1756285617746640","DOI":"10.1177\/1756285617746640","article-title":"Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies","volume":"11","author":"Dalakas","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/WNL.0b013e3181b59a80","article-title":"Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy","volume":"73","author":"Kuijf","year":"2009","journal-title":"Neurology"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"577288","DOI":"10.1016\/j.jneuroim.2020.577288","article-title":"Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy","volume":"345","author":"Liberatore","year":"2020","journal-title":"J Neuroimmunol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"e1109","DOI":"10.1212\/NXI.0000000000001109","article-title":"Decrease in serum anti-MAG autoantibodies is associated with therapy response in patients with anti-MAG neuropathy: retrospective study","volume":"9","author":"H\u00e4nggi","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/mus.27954","article-title":"Anti-myelin-associated glycoprotein neuropathy: where do we stand?","volume":"68","author":"Stino","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s00415-019-09367-0","article-title":"Relevance of anti-HNK1 antibodies in the management of anti-MAG neuropathies","volume":"266","author":"Delmont","year":"2019","journal-title":"J Neurol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision","volume":"28","author":"van den Bergh","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1182\/blood.2020007092","article-title":"CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies","volume":"136","author":"le Cann","year":"2020","journal-title":"Blood"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/mus.24192","article-title":"Acute and chronic ataxic neuropathies with disialosyl antibodies: a continuous clinical spectrum and a common pathophysiological mechanism","volume":"49","author":"Yuki","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1093\/brain\/124.10.1968","article-title":"The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies","volume":"124","author":"Willison","year":"2001","journal-title":"Brain"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1007\/s00415-018-8853-4","article-title":"CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA)","volume":"265","author":"Garcia-Santibanez","year":"2018","journal-title":"J Neurol"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1111\/ene.15523","article-title":"Anti-disialosyl-immunoglobulin M chronic autoimmune neuropathies: a nationwide multicenter retrospective study","volume":"29","author":"Peillet","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1159\/000116045","article-title":"Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia","volume":"25","author":"Roth","year":"2004","journal-title":"Psychiatr Neurol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ana.410240113","article-title":"A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside","volume":"24","author":"Pestronk","year":"1988","journal-title":"Ann Neurol"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1136\/jnnp-2019-321532","article-title":"Multifocal motor neuropathy: controversies and priorities","volume":"91","author":"Yeh","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrneurol.2011.175","article-title":"Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies","volume":"8","author":"Vlam","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1212\/WNL.47.4.951","article-title":"The sensitivity and specificity of anti-GM1 antibody testing","volume":"47","author":"Taylor","year":"1996","journal-title":"Neurology"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"e0125339","DOI":"10.1371\/journal.pone.0125339","article-title":"Anti-ganglioside antibodies in amyotrophic lateral sclerosis revisited","volume":"10","author":"Kollewe","year":"2015","journal-title":"PLoS One"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"637640","DOI":"10.1001\/archneur.1980.00500590061010","article-title":"Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy","volume":"37","author":"Dalakas","year":"1980","journal-title":"Arch Neurol"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1212\/CON.0000000000001461","article-title":"Autoimmune neuromuscular disorders associated with neural antibodies","volume":"30","author":"Dubey","year":"2024","journal-title":"Continuum"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1212\/WNL.0000000000004803","article-title":"Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases","volume":"90","author":"Dubey","year":"2018","journal-title":"Neurology"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"e1873","DOI":"10.1212\/WNL.0000000000008472","article-title":"Amphiphysin-IgG autoimmune neuropathy: a recognizable clinicopathologic syndrome","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/NEN.0b013e31824d1df2","article-title":"The collapsin response mediator protein 5 onconeural protein is expressed in Schwann cells under axonal signals and regulates axon-Schwann cell interactions","volume":"71","author":"Camdessanch\u00e9","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/WCO.0000000000000475","article-title":"Paraneoplastic neuropathies","volume":"30","author":"Antoine","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"e1014","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1046\/j.1468-1331.1999.610071.x","article-title":"Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies","volume":"6","author":"Willison","year":"1999","journal-title":"Eur J Neurol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.neurol.2023.02.064","article-title":"Clinical and pathophysiological implications of autoantibodies in autoimmune neuropathies","volume":"179","author":"Collet","year":"2023","journal-title":"Rev Neurol"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1111\/ene.16073","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome","volume":"30","author":"van Doorn","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1529-8027.2010.00290.x","article-title":"European Federation of Neurological Societies\/peripheral nerve society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the peripheral nerve society \u2013 first revision","volume":"15","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/WCO.0000000000001107","article-title":"Autoimmune nodopathies, an emerging diagnostic category","volume":"35","author":"Mart\u00edn-Aguilar","year":"2022","journal-title":"Curr Opin Neurol"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/ana.23794","article-title":"Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy","volume":"73","author":"Querol","year":"2013","journal-title":"Ann Neurol"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1093\/brain\/aww189","article-title":"Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy","volume":"139","author":"Doppler","year":"2016","journal-title":"Brain"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1212\/WNL.0000000000000205","article-title":"Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg","volume":"82","author":"Querol","year":"2014","journal-title":"Neurology"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1093\/brain\/awx124","article-title":"Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy","volume":"140","author":"Delmont","year":"2017","journal-title":"Brain"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.nmd.2016.10.008","article-title":"Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with antiNeurofascin 155 antibodies","volume":"27","author":"Vallat","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"e1098","DOI":"10.1212\/NXI.0000000000001129","article-title":"Clinical and laboratory features in anti-NF155 autoimmune Nodopathy","volume":"9","author":"Mart\u00edn-Aguilar","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"665136","DOI":"10.3389\/fneur.2021.665136","article-title":"Anti-Neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy\/combined central and peripheral demyelination: strategies for diagnosis and treatment based on the disease mechanism","volume":"12","author":"Kira","year":"2021","journal-title":"Front Neurol"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1212\/NXI.0000000000000771","article-title":"Contactin-1 autoimmunity: serologic, neurologic, and pathologic correlates","volume":"7","author":"Dubey","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"E19621","DOI":"10.1002\/mus.26392","article-title":"\u201cNeuro\u2010renal syndrome\u201d related to anti\u2010contactin\u20101 antibodies","volume":"59","author":"Taieb","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.expneurol.2016.10.006","article-title":"Complement deposition induced by binding of anti-contactin-1 auto-antibodies is modified by immunoglobulins","volume":"287","author":"Appeltshauser","year":"2017","journal-title":"Exp Neurol"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/brain\/awab014","article-title":"Antibodies to the Caspr1\/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"144","author":"Pascual-Go\u00f1i","year":"2021","journal-title":"Brain"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/acn3.51775","article-title":"Clinical profile of autoimmune nodopathy with anti-neurofascin 186 antibody","volume":"10","author":"Liu","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1111\/jns.12569","article-title":"Autoimmune nodo-paranodopathies 10\u2009years later: clinical features, pathophysiology and treatment","author":"Uncini","year":"2023","journal-title":"J Peripher Nerv Syst"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1212\/NXI.0000000000000603","article-title":"Anti-pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy","volume":"6","author":"Stengel","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"ref132","doi-asserted-by":"publisher","first-page":"e200081","DOI":"10.1212\/NXI.0000000000200081","article-title":"Anti-LGI4 antibody is a novel Juxtaparanodal autoantibody for chronic inflammatory demyelinating polyneuropathy","volume":"10","author":"Zhang","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1056\/NEJM200009213431204","article-title":"Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies","volume":"343","author":"Vernino","year":"2000","journal-title":"N Engl J Med"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jneuroim.2008.03.017","article-title":"Characterization of ganglionic acetylcholine receptor autoantibodies","volume":"197","author":"Vernino","year":"2008","journal-title":"J Neuroimmunol"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/mus.24559","article-title":"Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center","volume":"52","author":"Li","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.autneu.2008.11.013","article-title":"Antibody titers predict clinical features of autoimmune autonomic ganglionopathy","volume":"146","author":"Gibbons","year":"2009","journal-title":"Auton Neurosci"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.mayocp.2018.05.033","article-title":"Ganglionic antibody level as a predictor of severity of autonomic failure","volume":"93","author":"Cutsforth-Gregory","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.autneu.2008.10.022","article-title":"Other autonomic neuropathies associated with ganglionic antibody","volume":"146","author":"Sandroni","year":"2009","journal-title":"Auton Neurosci"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"102988","DOI":"10.1016\/j.autrev.2021.102988","article-title":"Autoimmune autonomic ganglionopathy: ganglionic acetylcholine receptor autoantibodies","volume":"21","author":"Urriola","year":"2022","journal-title":"Autoimmun Rev"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"e1162","DOI":"10.1212\/NXI.0000000000001162","article-title":"Novel cell-based assay for Alpha-3 nicotinic receptor antibodies detects antibodies exclusively in autoimmune autonomic Ganglionopathy","volume":"9","author":"Karagiorgou","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/brain\/awp136","article-title":"The pattern and diagnostic criteria of sensory neuronopathy: a case-control study","volume":"132","author":"Camdessanche","year":"2009","journal-title":"Brain"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1093\/brain\/awh605","article-title":"The wide spectrum of clinical manifestations in Sj\u00f6gren\u2019s syndrome-associated neuropathy","volume":"128","author":"Mori","year":"2005","journal-title":"Brain"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1136\/jnnp-2014-309730","article-title":"Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy","volume":"86","author":"Antoine","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/jnnp-2019-321849","article-title":"Clinical characterisation of sensory neuropathy with anti-FGFR3 autoantibodies","volume":"91","author":"Tholance","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1111\/ene.14180","article-title":"Clinical characteristics of fibroblast growth factor receptor 3 antibody-related polyneuropathy: a retrospective study","volume":"27","author":"Kovvuru","year":"2020","journal-title":"Eur J Neurol"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.neuroscience.2005.04.066","article-title":"Regulation of neuronal death and calcitonin gene-related peptide by fibroblast growth factor-2 and FGFR3 after peripheral nerve injury: evidence from mouse mutants","volume":"134","author":"Jungnickel","year":"2005","journal-title":"Neuroscience"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"e1032","DOI":"10.1212\/NXI.0000000000001032","article-title":"Argonaute autoantibodies as biomarkers in autoimmune neurologic diseases","volume":"8","author":"do","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"e200105","DOI":"10.1212\/NXI.0000000000200105","article-title":"Anti-AGO1 antibodies identify a subset of autoimmune sensory Neuronopathy","volume":"10","author":"Moritz","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"ref149","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/jnnp.45.1.83","article-title":"Subacute sensory neuropathy with remission: an association with lymphoma","volume":"45","author":"Sagar","year":"1982","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/jnnp.11.2.73","article-title":"Primary sensory neuropathy with muscular changes associated with carcinoma","volume":"11","author":"Denny-Brown","year":"1948","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/archneurol.2009.341","article-title":"Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers","volume":"67","author":"Giometto","year":"2010","journal-title":"Arch Neurol"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/brain\/awf006","article-title":"Paraneoplastic peripheral neuropathy associated with anti\u2010Hu antibodies","volume":"125","author":"Camdessanch\u00e9","year":"2002","journal-title":"Brain"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0092-8674(91)90184-Z","article-title":"HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and sex-lethal","volume":"67","author":"Szabo","year":"1991","journal-title":"Cell"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12883-016-0657-5","article-title":"Intrathecal synthesis of anti-Hu antibodies distinguishes patients with paraneoplastic peripheral neuropathy and encephalitis","volume":"16","author":"Schwenkenbecher","year":"2016","journal-title":"BMC Neurol"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/ana.410440620","article-title":"Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy","volume":"44","author":"Molinuevo","year":"1998","journal-title":"Ann Neurol"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1212\/01.WNL.0000144340.03364.BF","article-title":"Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes","volume":"63","author":"Llad\u00f3","year":"2004","journal-title":"Neurology"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1474-4422(14)70051-1","article-title":"A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study","volume":"13","author":"Sabater","year":"2014","journal-title":"Lancet Neurol"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"e962","DOI":"10.1212\/NXI.0000000000000962","article-title":"Anti-IgLON5 disease: A new bulbar-onset motor neuron mimic syndrome","volume":"8","author":"Werner","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"ref159","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1007\/s00415-022-11262-0","article-title":"Motor-neuron-disease-like phenotype associated with IgLON5 disease","volume":"269","author":"Sista","year":"2022","journal-title":"J Neurol"},{"key":"ref160","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/brain\/awac090","article-title":"Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease","volume":"146","author":"Gr\u00fcter","year":"2023","journal-title":"Brain"},{"key":"ref161","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00415-018-9143-x","article-title":"Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome","volume":"266","author":"Vogrig","year":"2019","journal-title":"J Neurol"},{"key":"ref162","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jns.2013.11.025","article-title":"Association of a paraneoplastic motor neuron disease with anti-Ri antibodies and a novel SOD1 I18del mutation","volume":"337","author":"Diard-Detoeuf","year":"2014","journal-title":"J Neurol Sci"},{"key":"ref163","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/ana.26050","article-title":"Leucine zipper 4 autoantibody: A novel germ cell tumor and paraneoplastic biomarker","volume":"89","author":"Dubey","year":"2021","journal-title":"Ann Neurol"},{"key":"ref164","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1474-4422(17)30329-0","article-title":"The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes","volume":"16","author":"Terkelsen","year":"2017","journal-title":"Neurology"},{"key":"ref165","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/ene.13508","article-title":"Associated conditions in small fiber neuropathy - a large cohort study and review of the literature","volume":"25","author":"de Greef","year":"2018","journal-title":"Eur J Neurol"},{"key":"ref166","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/mus.10301","article-title":"Sensory neuropathy with monoclonal IgM binding to a trisulfated heparin disaccharide","volume":"27","author":"Pestronk","year":"2003","journal-title":"Muscle Nerve"},{"key":"ref167","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/mus.23256","article-title":"Clinical and laboratory features of neuropathies with serum IgM binding to TS-HDS","volume":"45","author":"Pestronk","year":"2012","journal-title":"Muscle Nerve"},{"key":"ref168","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/mus.26748","article-title":"Cryptogenic small-fiber neuropathies: serum autoantibody binding to trisulfated heparan disaccharide and fibroblast growth factor receptor-3","volume":"61","author":"Levine","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref169","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.1007\/s00415-023-11798-9","article-title":"TS-HDS autoantibody: clinical characterization and utility from real-world tertiary care center experience","volume":"270","author":"Chompoopong","year":"2023","journal-title":"J Neurol"},{"key":"ref170","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/CND.0000000000000355","article-title":"Clinical features and treatment response in immune-mediated small Fiber neuropathy with Trisulfated heparin disaccharide or fibroblast growth factor receptor 3 antibodies","volume":"22","author":"Zeidman","year":"2021","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref171","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/jca.21944","article-title":"Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients","volume":"37","author":"Olsen","year":"2022","journal-title":"J Clin Apher"},{"key":"ref172","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.27745","article-title":"A double-blind placebo-controlled pilot study of immunoglobulin for small fiber neuropathy associated with TS-HDS and FGFR-3 autoantibodies","volume":"67","author":"Gibbons","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref173","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ana.25279","article-title":"A novel autoantibody against Plexin D1 in patients with neuropathic pain","volume":"84","author":"Fujii","year":"2018","journal-title":"Ann Neurol"},{"key":"ref174","doi-asserted-by":"publisher","first-page":"e819","DOI":"10.1212\/NXI.0000000000000819","article-title":"Painful trigeminal neuropathy associated with anti-Plexin D1 antibody","volume":"7","author":"Fujii","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"ref175","doi-asserted-by":"publisher","first-page":"e1028","DOI":"10.1212\/NXI.0000000000001028","article-title":"Antiplexin D1 antibodies relate to small Fiber neuropathy and induce neuropathic pain in animals","volume":"8","author":"Fujii","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"ref176","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/ana.26268","article-title":"Novel autoantibodies in idiopathic small Fiber neuropathy","volume":"91","author":"Chan","year":"2022","journal-title":"Ann Neurol"},{"key":"ref177","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1097\/WCO.0000000000000963","article-title":"Neuromuscular hyperexcitability syndromes","volume":"34","author":"De Wel","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"ref178","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/WCO.0000000000001104","article-title":"Autoimmune neuromyotonia","volume":"35","author":"Comperat","year":"2022","journal-title":"Curr Opin Neurol"},{"key":"ref179","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/jnnp-2017-315720","article-title":"LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes","volume":"89","author":"Binks","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref180","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.neuron.2018.01.033","article-title":"Immune or genetic-mediated disruption of CASPR2 causes pain hypersensitivity due to enhanced primary afferent excitability","volume":"97","author":"Dawes","year":"2018","journal-title":"Neuron"},{"key":"ref181","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/ene.13922","article-title":"Acquired neuromyotonia in thymoma-associated myasthenia gravis: a clinical and serological study","volume":"26","author":"Gastaldi","year":"2019","journal-title":"Eur J Neurol"},{"key":"ref182","doi-asserted-by":"publisher","first-page":"105537","DOI":"10.1016\/j.nbd.2021.105537","article-title":"Role of LGI1 protein in synaptic transmission: from physiology to pathology","volume":"160","author":"Fels","year":"2021","journal-title":"Neurobiol Dis"},{"key":"ref183","doi-asserted-by":"publisher","first-page":"awae302","DOI":"10.1093\/brain\/awae302","article-title":"A role for leucine-rich, glioma inactivated 1 in regulating pain sensitivity","author":"Farah","year":"2024","journal-title":"Brain"},{"key":"ref184","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/mus.20307","article-title":"Rippling muscle disease may be caused by \"silent\" action potentials in the tubular system of skeletal muscle fibers","volume":"31","author":"Lamb","year":"2005","journal-title":"Muscle Nerve"},{"key":"ref185","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/90050","article-title":"Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease","volume":"28","author":"Betz","year":"2001","journal-title":"Nat Genet"},{"key":"ref186","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/jamaneurol.2022.1357","article-title":"Identification of Caveolae-associated protein 4 autoantibodies as a biomarker of immune-mediated rippling muscle disease in adults","volume":"79","author":"Dubey","year":"2022","journal-title":"JAMA Neurol"},{"key":"ref187","doi-asserted-by":"publisher","first-page":"e200068","DOI":"10.1212\/NXI.0000000000200068","article-title":"Immune-mediated rippling muscle disease associated with thymoma and anti-MURC\/ cavin-4 autoantibodies","volume":"10","author":"Svahn","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref188","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O'Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"key":"ref189","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"ref190","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"ref191","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref192","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"key":"ref193","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","article-title":"Immune-mediated necrotizing myopathy","volume":"20","author":"Pinal-Fernandez","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"ref194","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"ref195","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/acr.22163","article-title":"Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement","volume":"66","author":"Kaji","year":"2014","journal-title":"Arthritis Care Res"},{"key":"ref196","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.nmd.2024.03.001","article-title":"272nd ENMC international workshop: 10 years of progress - revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16-18 June 2023, Hoofddorp, The Netherlands","volume":"37","author":"Lilleker","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"ref197","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5\u2032-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Benjamin Larman","year":"2013","journal-title":"Ann Neurol"},{"key":"ref198","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/acr.22600","article-title":"Cytosolic 5\u2032-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases","volume":"68","author":"Lloyd","year":"2016","journal-title":"Arthritis Care Res"},{"key":"ref199","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3389\/fimmu.2019.00745","article-title":"Anti-NT5c1A autoantibodies as biomarkers in inclusion body myositis","volume":"10","author":"Amlani","year":"2019","journal-title":"Front Immunol"},{"key":"ref200","doi-asserted-by":"publisher","first-page":"e0284409","DOI":"10.1371\/journal.pone.0284409","article-title":"Clinical significance of anti-NT5c1A autoantibody in Korean patients with inflammatory myopathies","volume":"18","author":"Lee","year":"2023","journal-title":"PLoS One"},{"key":"ref201","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology"},{"key":"ref202","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/rir-2022-0001","article-title":"Myositis-specific antibodies: overview and clinical utilization","volume":"3","author":"Halilu","year":"2022","journal-title":"Immunol Res"},{"key":"ref203","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","article-title":"Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay","volume":"49","author":"Ghirardello","year":"2010","journal-title":"Rheumatology"},{"key":"ref204","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.nmd.2022.05.011","article-title":"256th ENMC international workshop: myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8-10 October 2021","volume":"32","author":"Damoiseaux","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"ref205","doi-asserted-by":"publisher","first-page":"e209725","DOI":"10.1212\/WNL.0000000000209725","article-title":"Antibodies in autoimmune neuropathies: what to test, how to test, why to test","volume":"103","author":"Pascual-Go\u00f1i","year":"2024","journal-title":"Neurology"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1495205\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T14:11:34Z","timestamp":1730470294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1495205\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":205,"alternative-id":["10.3389\/fneur.2024.1495205"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1495205","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"article-number":"1495205"}}